Clinical trial
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel &…
NCT00343083 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00343083 |
|---|---|
| Title | Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) |
| Official title | A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of Head and Neck |
| Intervention type | Drug, Radiation |
| Interventions | Erbitux, Paclitaxel & Carboplatin, Radiation |
| Enrollment | 43 |
| Start date | Dec 1, 2004 |
| Primary completion | Jun 1, 2011 |
| Completion | May 1, 2012 |
| First posted | Jun 22, 2006 |
| Last update posted | Aug 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: